Figure 5.

Treatment effect of TMSCs in the acute murine colitis model. (A) In the acute colitis model, the macroscopic DAI scores, based on rectal bleeding, stool consistency, and body weight loss, were significantly lower in the TMSC-treated group compared to the DSS + PBS group (p = 0.006). (B) Body weight loss (%) in the TMSC-treated group was significantly lower than that in the DSS + PBS group (-19.2 ± 7.0 vs. -6.5 ± 2.8; p < 0.001). (C) In the TMSC-treated group, colitis-associated colon length shortening in the acute DSS colitis model was recovered (66.0 ± 2.2 vs. 77.3 ± 3.1, p = 0.007). (D) mRNA expressions of IL-1β, IL-6, IL-17, and TNFα were significantly downregulated in the TMSC-treated group compared to the DSS + PBS group. DSS, dextran sulfate sodium; PBS, phosphate-buffered saline; TMSC, tonsil-derived mesenchymal stem cell; DAI, disease activity index.